BioLife Solutions

BLFS

Market cap $1.33B

BioLife Solutions, Inc. (BLFS) Q1 2026 Earnings Call Transcript

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.04 per share a year ago.

Total revenue of $27.5 million, up 25% over Q1 2025 GAAP gross margin and non-GAAP adjusted gross margin of 64% GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash.

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

BOTHELL, Wash., April 23, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2026 first quarter financial results will be released on May 7, 2026.

Award Recognizes Technologies That Address Important Industry Needs and Advance Prior Standards BOTHELL, Wash., April 21, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced it has received the INTERPHEX 2026 Biotech Innovation Award for its CellSeal® CryoCase, a rigid cryogenic containment system purpose-built for frozen biologic materials.

The average of price targets set by Wall Street analysts indicates a potential upside of 70.8% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

The heavy selling pressure might have exhausted for BioLife Solutions (BLFS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

BioLife Solutions has executed a successful turnaround by refocusing on core biopreservation media and vials, divesting non-core assets. BLFS expects 17–20% revenue growth in FY26, positive GAAP net income, and mid-60s gross margins, supported by dominant CGT market share. Strategic acquisitions like PanTHERA and partnerships such as QKine are set to drive ARPU expansion and next-gen product launches by late 2026.

The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 35% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.